Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.47 |
| ▸ | SRC | P12931 | 7/20 | 0.47 |
| ▸ | BRAF | P15056 | 9/20 | 0.44 |
| ▸ | RAF1 | P04049 | 8/20 | 0.44 |
| ▸ | KRAS | P01116 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.44 |
| ▸ | ARAF | P10398 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062175 | 0.92 | BRAF (0.54) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL5062161 | 0.85 | FGFR1 (0.55) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL5062576 | 0.84 | KIT (0.66) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL5065211 | 0.83 | BRAF (0.49) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL22538096 | 0.82 | FGFR1 (0.55) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL4426658 | 0.81 | BRAF (0.49) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL4426394 | 0.81 | BRAF (0.48) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL4423868 | 0.81 | FGFR1 (0.56) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL4427156 | 0.81 | BRAF (0.49) | KITPDGFRAFGFR1SRCBRAF | |
| SCHEMBL5065239 | 0.81 | BRAF (0.46) | KITPDGFRAFGFR1SRCBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | KIT 2755/4885PDGFRA 2199/4885FGFR1 577/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | KIT 2755/4885PDGFRA 2199/4885FGFR1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.